Baizencell Becomes First Korean Company Selected for Oral Presentation of Cell Therapy Clinical Data at ASCO

Baizencell, a biopharmaceutical company specializing in new drug development, announced on April 22 that the Phase 2 clinical trial results for its cell therapy product, 'VT-EBV-N,' have been selected for an official oral abstract session at the 'American Society of Clinical Oncology (ASCO) 2026.'

VaizenCell Company Logo Image. VaizenCell

원본보기 아이콘

ASCO is the world's largest clinical oncology conference, where changes to treatment standards are discussed based on actual patient data. The 2026 event will be held in Chicago, USA, from May 29 to June 2.

According to Baizencell, this selection marks the first time that a domestic company has been chosen to present clinical cell therapy data in an official oral session at ASCO. The presentation will be delivered by Professor Jeon Youngwoo of Yeouido St. Mary's Hospital, who led the clinical trial.

Through this presentation, Baizencell plans to highlight the clinical achievements of 'VT-EBV-N,' focusing on 'recurrence prevention' and 'extension of survival period,' both of which are considered major challenges in cancer treatment. The Phase 2 clinical trial demonstrated that 'VT-EBV-N' produced significant effects in reducing the risk of recurrence and improving survival, suggesting the potential to enhance patient prognosis. In cancer therapy, recurrence is a key factor that drastically lowers patient survival rates, and effective strategies to prevent it remain an unmet need.

Baizencell CEO Ki Pyungseok stated, "Protecting patients' lives from the threat of recurrence is the ultimate goal of cancer treatment, and 'VT-EBV-N' has proven this potential with real clinical data." He added, "Being recognized for our technology at ASCO, we will accelerate the realization of global partnerships to enhance our corporate value and offer new therapeutic options for patients."

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.